The study, conducted at a hospital in Spain from 2015 to 2017, included all 100 patients who were switched to the biosimilar from the reference infliximab when the hospital transitioned to using the lower-cost product.
While it is becoming more common to switch patients with inflammatory bowel disease (IBD) to biosimilar CT-P13 (Inflectra, Remsima) from the reference infliximab (Remicade), long-term follow-up data is lacking. However, in one newly published study from a single-center, researchers reported that, at 2 years, most patients who switched continued on the biosimilar.
The study, conducted at a hospital in Spain from 2015 to 2017, included all 100 patients with moderate to severe Crohn disease (CD) (n = 64) or ulcerative colitis (UC) (n = 36) who were switched to the biosimilar from the reference infliximab when the hospital transitioned to using the lower-cost biosimilar.
The study’s primary end point was to analyze loss of response to infliximab after the switch.
The investigators found that, at 2 years, 72% of patients remained on the biosimilar. In total, 15% discontinued after loss of response, 4% discontinued due to adverse events (AEs), and 8% discontinued due to remission. One patient who achieved remission was switched to a different biologic after developing episcleritis. A total of 22% of patients required dose escalation during the follow-up period.
At the beginning of the study, 78% of patients were in remission. At 12, 18, and 24 months, 69.6%, 69.9%, and 68.5%, respectively, remained in remission. Among those who lost response, there was a median time to discontinuation of 15 months (range, 8-24).
By disease type, at 2 years, 25% of the patients with CD had discontinued (10 for loss of response, 3 because of clinical remission, 2 because of AEs, and 1 because of another medical indication). In the UC group, 33.33% of patients had discontinued at 2 years (5 for loss of response, 5 because of remission, and 2 because of AEs).
A total of 14% of patients experienced AEs, which included skin reactions, asthenia, headache, paresthesia during infusion, and other AEs. Six patients were admitted to the hospital for AEs.
Two patients, both in the CD group, developed antidrug antibodies over 18 months of follow-up. One of these patients achieved remission and discontinued treatment, while the other switched to adalimumab.
According to the authors, this study demonstrates the long-term efficacy of CT-P13 after a switch, and they add that the tranistion to the biosimilar saved the healthcare system €3000 (US $3379.50) per patient per year.
Reference
Veloz MFG, Jiménex MB, Delgado TV, et al. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data [published online June 18, 2019]. Therap Adv Gastroenterol. doi: 10.1177/1756284819858052.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.